Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Early Diabetic Nephropathy with Type 1 Diabetes
NCT06532682Phase 4Active, not recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in diabetic kidney disease (DKD) (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Urinary albumin-to-creatinine ratio at 24 weeks and estimated Glomerular Filtration Rate at 24 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06532682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532682.